JP2022505445A5 - - Google Patents

Info

Publication number
JP2022505445A5
JP2022505445A5 JP2021521481A JP2021521481A JP2022505445A5 JP 2022505445 A5 JP2022505445 A5 JP 2022505445A5 JP 2021521481 A JP2021521481 A JP 2021521481A JP 2021521481 A JP2021521481 A JP 2021521481A JP 2022505445 A5 JP2022505445 A5 JP 2022505445A5
Authority
JP
Japan
Prior art keywords
sequence
seq
antibody
antibody according
heavy chain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021521481A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022505445A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/058325 external-priority patent/WO2020087065A1/en
Publication of JP2022505445A publication Critical patent/JP2022505445A/ja
Publication of JP2022505445A5 publication Critical patent/JP2022505445A5/ja
Pending legal-status Critical Current

Links

JP2021521481A 2018-10-26 2019-10-28 Cd38に結合する重鎖抗体 Pending JP2022505445A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862751520P 2018-10-26 2018-10-26
US62/751,520 2018-10-26
PCT/US2019/058325 WO2020087065A1 (en) 2018-10-26 2019-10-28 Heavy chain antibodies binding to cd38

Publications (2)

Publication Number Publication Date
JP2022505445A JP2022505445A (ja) 2022-01-14
JP2022505445A5 true JP2022505445A5 (cg-RX-API-DMAC7.html) 2022-11-08

Family

ID=68610322

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021521481A Pending JP2022505445A (ja) 2018-10-26 2019-10-28 Cd38に結合する重鎖抗体

Country Status (11)

Country Link
US (1) US20210388106A1 (cg-RX-API-DMAC7.html)
EP (1) EP3870611A1 (cg-RX-API-DMAC7.html)
JP (1) JP2022505445A (cg-RX-API-DMAC7.html)
KR (1) KR20210086651A (cg-RX-API-DMAC7.html)
CN (1) CN112955467A (cg-RX-API-DMAC7.html)
AU (1) AU2019367218A1 (cg-RX-API-DMAC7.html)
BR (1) BR112021000173A2 (cg-RX-API-DMAC7.html)
CA (1) CA3100232A1 (cg-RX-API-DMAC7.html)
IL (1) IL282590A (cg-RX-API-DMAC7.html)
MX (1) MX2021004732A (cg-RX-API-DMAC7.html)
WO (1) WO2020087065A1 (cg-RX-API-DMAC7.html)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL299221A (en) 2016-06-21 2023-02-01 Teneobio Inc Cd3 binding antibodies
CN109862784A (zh) 2016-08-24 2019-06-07 特尼奥生物股份有限公司 产生经修饰的仅有重链的抗体的转基因非人动物
CR20220578A (es) 2016-09-14 2023-01-17 Teneobio Inc Anticuerpos de unión a cd3
EP3559035A1 (en) 2016-12-21 2019-10-30 TeneoBio, Inc. Anti-bcma heavy chain-only antibodies
JP7240335B2 (ja) 2017-06-20 2023-03-15 テネオワン, インコーポレイテッド 抗bcma重鎖のみ抗体
EA202091557A1 (ru) 2017-12-22 2020-11-18 Тенеобио, Инк. Антитела, содержащие только тяжелые цепи, которые связываются с cd22
CA3133654A1 (en) 2019-04-05 2020-10-08 Teneobio, Inc. Heavy chain antibodies binding to psma
CN114206927B (zh) 2019-06-14 2025-03-21 特尼奥生物股份有限公司 与cd22和cd3结合的多特异性重链抗体
WO2022271987A1 (en) * 2021-06-23 2022-12-29 TeneoFour, Inc. Anti-cd38 antibodies and epitopes of same
US20250277051A1 (en) * 2021-08-02 2025-09-04 Hangzhou Unogen Biotech, Ltd Anti-cd38 antibodies, anti-cd3 antibodies, and bispecific antibodies, and uses thereof
CN119403837A (zh) * 2022-06-08 2025-02-07 上海华奥泰生物药业股份有限公司 Cd39/cd73双特异性抗原结合蛋白及其用途

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US6548640B1 (en) 1986-03-27 2003-04-15 Btg International Limited Altered antibodies
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
EP0590058B1 (en) 1991-06-14 2003-11-26 Genentech, Inc. HUMANIZED Heregulin ANTIBODy
US6096871A (en) 1995-04-14 2000-08-01 Genentech, Inc. Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life
CA2249195A1 (en) 1996-03-18 1997-09-25 Board Of Regents, The University Of Texas System Immunoglobin-like domains with increased half lives
GB0115256D0 (en) 2001-06-21 2001-08-15 Babraham Inst Mouse light chain locus
KR100944575B1 (ko) * 2002-10-17 2010-02-25 젠맵 에이/에스 Cd20에 대한 인간 모노클로날 항체
MXPA05004677A (es) 2002-10-31 2005-11-17 Genentech Inc Metodos y composiciones para aumentar la produccion de anticuerpos.
WO2004065417A2 (en) 2003-01-23 2004-08-05 Genentech, Inc. Methods for producing humanized antibodies and improving yield of antibodies or antigen binding fragments in cell culture
MXPA06008700A (es) 2004-02-06 2007-01-19 Morphosys Ag Anticuerpos anti-cd38 humanos y usos para los mismos.
EP1776383B1 (en) 2004-07-22 2014-08-20 Erasmus University Medical Center Rotterdam Binding molecules
US20160355591A1 (en) 2011-05-02 2016-12-08 Immunomedics, Inc. Subcutaneous anti-hla-dr monoclonal antibody for treatment of hematologic malignancies
EP2551282A3 (en) 2005-03-23 2013-02-13 Genmab A/S Antibodies against CD38 for treatment of multiple myeloma
CN101287764B (zh) 2005-10-12 2013-11-13 莫佛塞斯公司 特异性针对人CD38的完全人HuCAL GOLD-衍生治疗抗体的生成和鉴定
AU2006312148B2 (en) 2005-11-07 2012-04-12 The Rockefeller University Reagents, methods and systems for selecting a cytotoxic antibody or variant thereof
US20100021473A1 (en) * 2005-12-06 2010-01-28 Domantis Limited Bispecific Ligands With Binding Specificity to Cell Surface Targets and Methods of Use Therefor
AU2007235413B2 (en) 2006-04-05 2012-08-02 The Rockefeller University Polypeptides with enhanced anti-inflammatory and decreased cytotoxic properties and relating methods
EP1914242A1 (en) 2006-10-19 2008-04-23 Sanofi-Aventis Novel anti-CD38 antibodies for the treatment of cancer
US20100122358A1 (en) 2008-06-06 2010-05-13 Crescendo Biologics Limited H-Chain-only antibodies
CN102421801B (zh) 2009-03-10 2016-03-16 比奥根Ma公司 抗-bcma抗体
GB0905023D0 (en) 2009-03-24 2009-05-06 Univ Erasmus Medical Ct Binding molecules
TWI507525B (zh) * 2009-06-26 2015-11-11 Regeneron Pharma 具天然免疫球蛋白形式之易分離的雙專一性抗體
US9345661B2 (en) 2009-07-31 2016-05-24 Genentech, Inc. Subcutaneous anti-HER2 antibody formulations and uses thereof
EP2580243B1 (en) 2010-06-09 2019-10-16 Genmab A/S Antibodies against human cd38
JOP20210044A1 (ar) 2010-12-30 2017-06-16 Takeda Pharmaceuticals Co الأجسام المضادة لـ cd38
AU2012236210B2 (en) * 2011-04-01 2016-02-04 Immunogen, Inc. CD37-binding molecules and immunoconjugates thereof
AP2016009222A0 (en) * 2013-11-04 2016-05-31 Glenmark Pharmaceuticals Sa Production of t cell retargeting hetero-dimeric immunoglobulins
PL3122781T3 (pl) * 2014-03-28 2020-06-15 Xencor, Inc. Dwuswoiste przeciwciała, które wiążą się z CD38 i CD3
CR20170526A (es) * 2015-05-20 2018-04-03 Janssen Biotech Inc ANTICUERPOS ANTI-CD38 PARA EL TRATAMIENTO DE AMILOIDOSIS DE CADENA LIGERA y OTRAS ENFERMEDADES MALIGNAS HEMATOLÓGICAS POSITIVAS PARA CD38
CN105384825B (zh) * 2015-08-11 2018-06-01 南京传奇生物科技有限公司 一种基于单域抗体的双特异性嵌合抗原受体及其应用
EP3374397A2 (en) * 2015-11-10 2018-09-19 University Medical Center Hamburg - Eppendorf Antigen-binding polypeptides directed against cd38
IL299221A (en) 2016-06-21 2023-02-01 Teneobio Inc Cd3 binding antibodies
CN109862784A (zh) 2016-08-24 2019-06-07 特尼奥生物股份有限公司 产生经修饰的仅有重链的抗体的转基因非人动物
CR20220578A (es) 2016-09-14 2023-01-17 Teneobio Inc Anticuerpos de unión a cd3
EP3559035A1 (en) * 2016-12-21 2019-10-30 TeneoBio, Inc. Anti-bcma heavy chain-only antibodies

Similar Documents

Publication Publication Date Title
JP2021530236A5 (cg-RX-API-DMAC7.html)
JP2024507540A5 (cg-RX-API-DMAC7.html)
JP7570338B2 (ja) クローディン6抗体及びその使用
RU2742691C2 (ru) Cd3-связывающий домен
JP2025109759A5 (cg-RX-API-DMAC7.html)
JP6676521B2 (ja) 二重特異性分子、薬学的組成物及びそれらの使用
JP2022537931A5 (cg-RX-API-DMAC7.html)
JP2022526595A5 (cg-RX-API-DMAC7.html)
CN113195530B (zh) 抗体融合蛋白、制备方法及其应用
JP2018502050A5 (cg-RX-API-DMAC7.html)
CN118063619A (zh) 工程化的异源二聚体蛋白质
JP2020530306A (ja) 多重特異性抗体とその作製及び使用方法
CN109796532B (zh) 靶向成纤维激活蛋白α的结合单元及其应用
JP2014515598A (ja) 二重特異性三鎖抗体様分子
JP2024508808A5 (cg-RX-API-DMAC7.html)
JP2020530777A (ja) 多重特異性抗体とその作製及び使用方法
RU2010119450A (ru) Антитело против bst2
JP2024507693A5 (cg-RX-API-DMAC7.html)
JP2026510999A (ja) Cd19/cd38多重特異性抗体
CN106573985A (zh) 抗vasa抗体及其生产方法和用途
JP2018502068A5 (cg-RX-API-DMAC7.html)
KR20240163722A (ko) Ilt3 및 cd3 결합제 및 이의 사용 방법
JP2024516098A5 (cg-RX-API-DMAC7.html)
JP2022516301A (ja) Cd137アゴニスト性抗体とその使用
CN117843788A (zh) 一种抗gprc5d的抗体及其多特异性抗体和相关应用